ROHHAD Market

ROHHAD named after a group of symptoms, refers to Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation, and Autonomic Dysregulation. ROHHAD is a rare syndrome whose etiology is not yet known. It is a pediatric disorder which potentially could be fatal.

Symptoms of ROHHAD start appear in children generally after the age of 1-2 with rapid weight gain within a short span of six to 12-months span coupled with stunted height. The sequence of symptoms thereafter is hypothalamic and autonomic dysregulation. This is followed by behavioral issues.

Prior to onset of obesity, the children appear to be otherwise healthy. The clinical symptoms of ROHHAD appear as the patient’s age advances. Early diagnosis of disorder holds the key in treatment of ROHHAD. It is a very rare disorder with only over 100 cases identified worldwide.

ROHHAD essentially involves loss of respiratory control and autonomic nervous system (ANS) regulation, along with abnormalities in endocrine system. The disorder was first recognized in 1965. Currently, the cause of ROHHAD is known, however scholars suspect it to be a genetic disease.

With novel diseases like COVID-19, disorders like ROHHAD demand more recognition and research since children suffering from ROHHAD constitute vulnerable group with compromised respiratory system.

Even though ROHHAD is extremely rare condition, examining its market becomes crucial because with development of gene therapies, understanding the commercial potential of orphan drugs and disorders has become lucrative for pharmaceutical industry.

Additionally, various governments’ nudge at policy level to the industry to invest more in therapeutics for rare diseases has contributed positively in the growth of rare diseases treatment market. As a result, the industry is now keen to understand rare diseases as a drug discovery strategy.

With approximately 300 million people being affected by rare diseases worldwide, the global niche market is sure to realize positive growth. One of the most significant restrainers for the ROHHAD is misdiagnosis. Since the symptoms are not unique and manifest at different ages, they are often considered stand alone and not correlated.

Absence of dedicated departments for diagnosis of rare syndromes/disorders in the healthcare centers worldwide adds to the list of limitations. The lack of awareness for rare disease in general and for ROHHAD in particular furthermore contributes to existing challenges.

With advance cutting-edge technology in diagnosis and treatment, visibility and awareness for rare disorders is bound to see growth which in turn would drive market for treatment for rare diseases in general and for ROHHAD in particular. Since, 50-60% of ROHHAD patient die due to cardiopulmonary arrest, treating hypoventilation becomes the most crucial aspect of treatment.

Hence, by indication type, hypoventilation medication segment seems to register robust growth in the global ROHHAD treatment market. By distribution channel wise, hospital pharmacies are expected to witness steady growth due to need to medication to be given under specialist supervision.

North America, mostly, the USA and Canada account for the major market share of the global ROHHAD treatment market because of more developed market and high investment in research and development by major universities and pharmaceutical industry. Europe will continue to hold the second largest chunk in the global ROHHAD treatment market owing to advanced government policies.

With cases being discovered in India, Malaysia and Japan, the global ROHHAD market in Asia-Pacific is also expected to see some major disruptions in the future. Middle East and Africa will continue to remain least attractive in the global ROHHAD treatment market owing to the lack of awareness and less financial spending on healthcare in general.    

The key participants operating in the global ROHHAD treatment market are Novo Nordisk, Eli Lilly, Amgen, Boehringer Ingelheim, Pfizer Inc., AbbVie Inc., Merck, Endo Pharmaceuticals Solutions Inc., Allergan, Johnson & Johnson, AstraZeneca.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Europe (Germany, U.K, France, Italy, Spain)
• South Asia (India, ASEAN Countries)
• East Asia (Japan, China & South Korea)
• Oceania (Australia & New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint